Dr Sridhar Chaganti, University Hospital, Birmingham NHS Foundation Trust, UK. by Christine Clark: In general the outcomes of treatment for diffuse large B-cell lymphoma (DLBCL) are good –… read more.
Professor Karl Peggs, University College, London. by Christine Clark: There are numerous regimens for salvage treatment of Hodgkin lymphoma and all are associated with an overall response rate… read more.
Rethinking risk for better outcomes in ASCT by Christine Clark Dr Craig Moskowitz, Memorial Sloan Kettering Cancer Center, NY, USA. Patient populations are changing – before 2010 all… read more.
Rethinking risk for better outcomes in ASCT by Christine Clark Dr Craig Moskowitz, Memorial Sloan Kettering Cancer Center, NY, USA. Patient populations are changing – before 2010 all… read more.
Allogeneic stem cell transplantation: still a role in CLL/lymphoma? by Christine Clark Professor Peter Dreger, Heidelberg University Hospital, Germany. The goal of allogeneic transplant therapy is to provide… read more.
Allogeneic stem cell transplantation: still a role in CLL/lymphoma? by Christine Clark Professor Peter Dreger, Heidelberg University Hospital, Germany. The goal of allogeneic transplant therapy is to provide… read more.
Charlotte Pawlyn and John R Jones (both of Institute of Cancer Research, London) and Ruth de Tute, St James’s University Hospital, Leeds. by Maria Dalby: Quadruplet therapy with… read more.
Professor Keith Stewart, Mayo Clinic, Scottsdale, AZ, USA. by Maria Dalby: The dramatic improvement in MM survival in the last 40 years is largely linked to the introduction… read more.
Genome-guided therapy in multiple myeloma by Maria Dalby Professor Keith Stewart, Mayo Clinic, Scottsdale, AZ, USA Genomic sequencing of newly-diagnosed and refractory MM patients shows that combination therapy… read more.
Genome-guided therapy in multiple myeloma by Maria Dalby Professor Keith Stewart, Mayo Clinic, Scottsdale, AZ, USA Genomic sequencing of newly-diagnosed and refractory MM patients shows that combination therapy… read more.
Risk stratification in the older patient: what are our priorities? by Maria Dalby Professor Sonja Zweegman, VU University Medical Centre, Amsterdam, NL Biological age and frailty, rather than… read more.